Skip to main content
SpringerLink
Log in

Biosimilare Antikörper in der Onkologie

Biosimilar antibodies in oncology

  • Sektion C
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Tabernero J, Vyas M, Giuliani R et al (2017) Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open 1(6):e142

    Article  PubMed  PubMed Central  Google Scholar 

  2. Deutsche Gesellschaft für Hämotologie und Onkologie. Positionspapier Biosimilars von monoklonalen Antikörpern in der Medizinischen Onkologie (2017) https://www.dgho.de/informationen/stellungnahmen/patientenversorgung/Positionspapier_Biosimilars.pdf: 21.6.2017. Zugegriffen: 30.05.2017

  3. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues: 30.05.2012.

  4. Mellstedt H (2013) Anti-neoplastic biosimilars – the same rules as for cytotoxic generics cannot be applied. Ann Oncol 24(Suppl 5):v23–v28

    Article  PubMed  Google Scholar 

  5. Cortes J, Curigliano G, Dieras V (2014) Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 144((2):233–239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Coiffier B, Thieblemont C, van den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Récher C, Coiffier B, Haioun C et al (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B‑cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378((9806):1858–1867

    Article  PubMed  Google Scholar 

  8. Cabanillas F (2013) Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? J Clin Oncol 31(1):14–16

    Article  PubMed  Google Scholar 

  9. Ludwig WD, Dicheva S (2016) Biosimilars in der Onkologie: Eine therapeutische Alternative zu Referenzarzneimitteln? Z Gastroenterol 54(11):1223–1229

    Article  CAS  PubMed  Google Scholar 

  10. O’Brien SM, Kantarjian H, Thomas DA et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19(8):2165–2170

    Article  PubMed  Google Scholar 

  11. Coiffier B, Haioun C, Ketterer N et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92(6):1927–1932

    CAS  PubMed  Google Scholar 

  12. Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40(2):205–211

    Article  CAS  Google Scholar 

  13. Jurczak W, Ilidia M, Govindbabu KS et al (2016) A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in patients with previously untreated Advanced Follicular Lymphoma. Blood 128(22):1809

    Google Scholar 

  14. Coiffier B, Sancho JM, Wojciech J et al (2016) Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed Advanced stage Follicular Lymphoma (AFL). Blood 128(22):1807

    Google Scholar 

  15. Bundesinstitut für Arzneimittel und Medizinprodukte. BfArM (2013) Arzneimittel unter zusätzlicher Überwachung. http://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/AM_zusUeb/_node.html. Zugegriffen: 23. Febr. 2017

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fachapothekerin für Arzneimittelinformation, Aulberstr. 8, 72764, Reutlingen, Deutschland

    Susanne Heinzl

Authors
  1. Susanne Heinzl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Heinzl.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heinzl, S. Biosimilare Antikörper in der Onkologie. Forum 32, 443–445 (2017). https://doi.org/10.1007/s12312-017-0321-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-017-0321-z

Search

Navigation